Number of Tables: 12
This IDC Health Insights report details IT spending expectations for the life science manufacturing and supply chain industry segment, which is currently projected to experience strengthening growth during 2012.
Eric Newmark, program director at IDC Health Insights, commented, "Life science companies are exploring opportunities to further optimize manufacturing and supply chain processes to help solve several industry challenges. Broader procurement diversification is needed to fight current drug shortages, outsourcing initiatives are expanding to facilitate further cost reduction and improve manufacturing agility, and serialization and drug pedigree progress remains critical to successfully reducing the explosion of counterfeit drugs. Additionally, initiatives like continuous manufacturing and quality by design (QbD) and Process Analytical Technology (PAT) aim to improve quality, reduce defects, streamline operations, and reduce corporate risk. All of these hold great long-term promise for life science companies and should help drive both top- and bottom-line expansion in the coming years."